Adjuvant Chemotherapy in Breast Cancer
Author Information
Author(s): J.M. Morrison, A. Howell, K.A. Kelly, R.J. Grieve, I.J. Monypenny, R.A. Walker, J.A.H. Waterhouse
Primary Institution: Selly Oak Hospital, Birmingham, UK
Hypothesis
The study aims to test the effectiveness of a combination chemotherapy regimen as an adjuvant treatment after mastectomy in patients with operable breast cancer and involved axillary lymph nodes.
Conclusion
The study found that adjuvant chemotherapy significantly prolonged relapse-free survival by a median of 14 months, but did not show a significant effect on overall survival.
Supporting Evidence
- Adjuvant chemotherapy improved the percentage of patients relapse-free at 5 years from 27% to 38%.
- The median relapse-free survival was prolonged by 14 months in the treated group.
- Significant prolongation of relapse-free survival was observed particularly in premenopausal patients.
Takeaway
Giving chemotherapy after breast cancer surgery helps patients stay cancer-free for longer, but it doesn't necessarily help them live longer.
Methodology
Patients were randomized to receive either no treatment or a combination chemotherapy regimen (AVCMF) after mastectomy, with follow-up assessments for relapse and survival.
Limitations
The study did not find a significant overall survival benefit, and the results may not apply to all patient demographics.
Participant Demographics
Patients included those with axillary lymph node involvement, aged below 65, with various tumor sizes and menopausal statuses.
Statistical Information
P-Value
0.0006
Confidence Interval
554-808 days and 836-1,290 days
Statistical Significance
p<0.05
Want to read the original?
Access the complete publication on the publisher's website